|
Rapid Therapeutic Science Laboratories Inc (PCHA) |
|
Rapid Therapeutic Science Laboratories Inc
PCHA's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Rapid Therapeutic Science Laboratories Inc 's sales fell
in II. Quarter 2023 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
deterioration of revenues by -8.1 %
Rapid Therapeutic Science Laboratories Inc realized net income compared to net loss a year ago in II. Quarter 2023
• More on PCHA's Growth
|
|
Rapid Therapeutic Science Laboratories Inc current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.
Rapid Therapeutic Science Laboratories Inc PEG ratio is at -7.68
Rapid Therapeutic Science Laboratories Inc realized cash reduction of $ -0.01 per share in trailing twelve-month period. |
Company |
791.79 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.39.
• More on PCHA's Valuation
|
|
|
|
|
Rapid Therapeutic Science Laboratories Inc current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.
Rapid Therapeutic Science Laboratories Inc PEG ratio is at -7.68
Rapid Therapeutic Science Laboratories Inc realized cash outflow of $ -0.01per share in trailing twelve-month period. |
Company |
791.79 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.39.
• More on PCHA's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com